| 11 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5   |  | EPA REGISTRATION NO.  | DATE OF ISSUANC   |
|--|--|---|---|
|  | ICE OF PESTICIDES PROGRAMS   | 19840-2   | 07050   |
| RE   | EGISTRATION DIVISION (WH-567)<br>WASHINGTON, D.C. 20460  | TERM OF ISSUANCE  | 07 DEC 1984   |
|  |  | NAME O PESTICIDE PRO  |   |
| NOTICE C   | OF PESTICIDE: RELEASE ATION  | Orecerve "R   | V. J. ex t. et  |
|  | the Federal Insecticide, Fungicide,<br>1 Rodenticide Act, as amended)  |   |   |
| NAME AND ADDR  | RESS OF REGISTRANT (Include ZIP code)  |   |   |
| ۲  |  | Г   |   |
| D:   | airy and Poods Jabs Inc.   |   |   |
| 1  | 750 Folsom Street  |   |   |
| Sa   | an Francisco, C <sup>2</sup> 94103   |   |   |
| L  |  |   | ST AVAILABLE COPY   |
| product always<br>On the basis of  | id accepted by the Registration Division pr<br>refer to the above U.S. EPA registration m<br>information furnished by the registrant, th<br>secticide. Eungivide, and Rodenticide Act.   | umber.<br>e above named pesticide is he   |   |
| ine reaeral ins  | secticide, Fungibide, and Rodenticide Act.   |   |   |
| A copy of the 1  | labeling accepted in connection with this R  | egistration/Reregistration is a   | returned herewith.  |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This  | in no way to be construed as an indorseme<br>environment, the Administrator, on his not<br>ance with the Act. The acceptance of any<br>e construed as giving the registrant a right<br>product is conditionally rec<br>ab provided that you:   | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name  | or cancel the registration of a<br>egistration of a product under t<br>or to its use if it has been cov   |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>3(c)(7)(7)<br>1.<br>c)f vour<br>repistran<br>2.<br>for chip<br>a.<br>3.   | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>construed as giving the registrant a right<br>product is conditionally red<br>Al provided that you:<br>Submit and/or cite all data to<br>product under FIFRA sec. 3(conte of similar products to 5)<br>Make the labeling changes li  | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>mistored in accordance<br>required for registry<br>(5) when the Agency<br>ubmit such data.<br>sted below before yo<br>tion No. 49840-2."  | or cancel the registration of a product under t<br>egistration of a product under t<br>or to its use if it has been cov<br>ce with FIFRA sec.<br>ation/reregistration<br>requires all<br>u release the produc   |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>3(c)(7)()<br>1.<br>of your<br>repistran<br>2.<br>for ship<br>a.<br>3.<br>humber a<br>4.   | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>e construed as giving the registrant a right<br>product is conditionally rec<br>Al provided that you:<br>Submit and/or cite all data is<br>product under FIFRA sec. 3(c<br>nte of similar products to si<br>Make the labeling changes li<br>ment:<br>Add the phrase "FFA Peristra"<br>The acute oral JDgo study su   | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>aighered in accordance<br>required for registry<br>(5) when the Agency<br>ubmit such data.<br>sted below before yo<br>tion No. 49840-2."<br>hmitted is acceptable<br>tement of Forumla da   | or cancel the registration of a product under t<br>egistration of a product under t<br>or to its use if it has been cov<br>ce with FIFRA sec.<br>ation/reregistration<br>reguires all<br>u release the product<br>e. The accession  |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>3(c)(7)(7)<br>1.<br>of your<br>repistran<br>2.<br>for ship<br>a.<br>3.<br>number a<br>4.<br>1994, is<br>5.<br>release   | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>construed as giving the registrant a right<br>product is conditionally rec<br>Al provided that you:<br>Submit and/or cite all data is<br>product under FIFRA sec. 3(c<br>nts of similar products to 5<br>Make the labeling changes li<br>ment:<br>Add the birase "FFA Peristra<br>The acute oral ID <sub>KO</sub> study su<br>salamed is 255004.   | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>aignered in accordance<br>required for requestry<br>(5) when the Agency<br>ubmit such data.<br>sted below before yo<br>tion No. 49840-2."<br>hmitted is accentable<br>tement of Forumla da<br>ced in your file.<br>ur final printed lab<br>efer to the A-79 Fnc   | or cancel the registration of a product under t<br>egistration of a product under t<br>or to its use if it has been cov<br>ce with FIFRA sec.<br>ation/reregistration<br>reguires all<br>u release the product<br>e. The accession<br>ted November 7,<br>weling before you  |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>A(c)(T)()<br>1.<br>of your<br>repistran<br>2.<br>for ship<br>A.<br>3.<br>tumber a<br>4.<br>1984, is<br>5.<br>rolease<br>Actript<br>1.<br>tumber a   | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>construed as giving the registrant a right<br>product is conditionally red<br>At provided that you:<br>Submit and/or cite all data is<br>product under FTFRA sec. 3(conts of similar products to 5)<br>Make the labeling changes li<br>ment:<br>Add the phrase "FFA Peristra<br>The acute oral IDKO study submit<br>science is 255004.<br>The revised Confidential Stat<br>acceptable and has been pla<br>Submit five (5) copies of yo<br>the product for shirment. R  | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>mistered in accordance<br>required for registro<br>(5) when the Agency<br>ubmit such data.<br>Sted below before your<br>tion No. 49840-2."<br>hmitted is accentable<br>tement of Forumla da<br>ced in your file.<br>ur final printed lab<br>efer to the A-79 Enc<br>d.<br>ifed with, the regist<br>with FTEPA sec. 66<br>acceptance of these<br>helowed for your rec  | or cancel the registration of a product under t<br>or to its use if it has been cov<br>Ce with FIFRA sec.<br>ation/reregistration<br>requires all<br>u release the product<br>e. The accession<br>ted November 7,<br>ted November 7,<br>eling before you<br>uesure for a further<br>chation will be<br>e). Your science to<br>conditions.                     |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>3(c)(7)(7)<br>1.<br>5(c)(7)(7)<br>7(c)(7)(7)<br>1.<br>5(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)  | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>construed as giving the registrant a right<br>product is conditionally red<br>Al provided that you:<br>Submit and/or cite all data is<br>product under FIFRA sec. 3(c)<br>nts of similar products to 50<br>Make the labeling changes li<br>ment:<br>Add the obrase "FFA Peristran<br>The acute oral JDKO study su<br>snioned is 255004.<br>The revised Confidential Stan<br>acceptable and has been pla<br>Submit five (5) copies of yo<br>the product for shirment. R<br>lon of final printed labelin<br>here conditions are not comp<br>to cancelistion in accordance<br>of the preduct constitutes  | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>mistored in accordance<br>required for registro<br>(5) when the Agency<br>ubmit such data.<br>Sted below before you<br>tion No. 49840-2."<br>hmitted is accentable<br>tement of Forumla da<br>ded in your file.<br>ur final printed lab<br>efer to the A-79 Enc<br>d.<br>ifed with, the redist<br>e with FTEPA sec. 66<br>acceptance of these<br>inclosed for your register.  | or cancel the registration of a product under t<br>or to its use if it has been cov<br>Ce with FIFRA sec.<br>ation/reregistration<br>requires all<br>u release the product<br>e. The accession<br>ted November 7,<br>ted November 7,<br>eling before you<br>uesure for a further<br>chation will be<br>e). Your science to<br>conditions.                     |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>3(c)(7)(7)<br>1.<br>5(c)(7)(7)<br>7(c)(7)(7)<br>1.<br>5(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)  | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>e construed as giving the registrant a right<br>product is conditionally rec<br>Al provided that you:<br>Submit and/or cite all data is<br>product under FIFRA sec. 3(c<br>ints of similar products to 5)<br>Make the labeling changes li<br>ment:<br>Add the birase "FPA Peristran<br>The acute oral IDgo study su<br>salamed is 255004.<br>The revised Confidential Star<br>acceptable and has been pla<br>Submit five (5) copies of yo<br>the product for shirment. R<br>ion of final printed labelin<br>here conditions are not comp<br>to categoriation in accordanc<br>of the preduct constitutes<br>ammed copy of the label is e            | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>mistered in accordance<br>required for registre<br>((5) when the Agency<br>ubmit such data.<br>sted below before yo<br>tion No. 49840-2."<br>bmitted is acceptable<br>tement of Forumla da<br>ced in your file.<br>ur final printed lab<br>efer to the A-79 Enc<br>d.<br>ifed with, the reais<br>e with FTEPA sec. 66<br>acceptance of these<br>miclored for your reg-<br>action B. Ice   | or cancel the registration of a product under t<br>ergistration of a product under t<br>or to its use if it has been cov<br>ce with FIFRA sec.<br>ation/reregistration<br>requires all<br>u release the produc<br>e. The accession<br>ted November 7,<br>ted November 7,<br>eling before you<br>resure for a further<br>conditions.<br>conditions.            |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>3(c)(7)(7)<br>1.<br>5(c)(7)(7)<br>7(c)(7)(7)<br>1.<br>5(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)<br>7(c)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)(7)(7)<br>7(c)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)   | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>e construed as giving the registrant a right<br>product is conditionally red<br>A) provided that you:<br>Submit and/or cite all data is<br>product under FTERA sec. 3(c<br>ints of similar products to 5)<br>Make the labeling changes li<br>ment:<br>Add the phrase "FPA Peristran<br>The acute oral IDKG study su<br>spicmed is 255004.<br>The revised Confidential Stat<br>acceptable and has been pla<br>Submit five (5) copies of yo<br>the product for shirment. R<br>ion of final printed labelin<br>here conditions are not comp<br>to cancellation in accordanc<br>of the preduct constitutes<br>ammed copy of the label is e             | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>mistered in accordance<br>required for registre<br>((5) when the Agency<br>ubmit such data.<br>sted below before yo<br>tion No. 49840-2."<br>bmitted is accentable<br>tement of Forumla da<br>ced in your file.<br>ur final printed lab<br>efer to the A-79 Enc<br>d.<br>ifed with, the redist<br>e with FTEPA sec. ((<br>acceptance of these<br>inclosed for your rec<br>action B. Ice<br>Product Manager (31)                             | or cancel the registration of a product under t<br>ergistration of a product under t<br>or to its use if it has been cov<br>ce with ETERA sec.<br>ation/reregistration<br>requires all<br>u release the produc<br>e. The accession<br>ted November 7,<br>whing before you<br>consure for a further<br>stration will be<br>e). Your riease to<br>conditions.   |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>A(c)(T)()<br>1.<br>of your<br>repistran<br>2.<br>for ship<br>A.<br>3.<br>tumber a<br>4.<br>1984, is<br>5.<br>rolease<br>Actript<br>1.<br>tumber a   | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>e construed as giving the registrant a right<br>product is conditionally red<br>A) provided that you:<br>Submit and/or cite all data is<br>product under FTFRA sec. 3(c<br>ints of similar products to 5)<br>Make the labeling changes li<br>ment:<br>Add the phrase "FFA Fecistran<br>The acute oral ID50 study su<br>snicmed is 255004.<br>The revised Confidential Star<br>acceptable and has been pla<br>Submit five (5) copies of yo<br>the product for shimment. R<br>ion of final printed labelin<br>have conditions are not comp<br>to cancellation in accordanc<br>of the preduct constitutes<br>amimed copy of the label is e            | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>mistered in accordance<br>required for registre<br>((5) when the Agency<br>ubmit such data.<br>sted below before yo<br>tion No. 49840-2."<br>bmitted is accentable<br>tement of Forumla da<br>ded in your file.<br>ur final printed lab<br>efer to the A-79 Enc<br>d.<br>ifed with, the redist<br>e with FTEPA sec. ((<br>acceptance of these<br>inclosed for your rec<br>d.<br>aoth R. Ice<br>Product Manager (31)<br>Disinfectants Branch | or cancel the registration of a product under t<br>ergistration of a product under t<br>or to its use if it has been cov<br>ce with FIFRA sec.<br>ation/reregistration<br>requires all<br>u release the produc<br>e. The accession<br>ted November 7,<br>whing before you<br>consure for a further<br>stration with he<br>e). Your pricase for<br>conditions. |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>3(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)<br>1.<br>(c)(7)(7)(7)<br>1.<br>(c)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)(7)  | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>e construed as giving the registrant a right<br>product is conditionally red<br>A) provided that you:<br>Submit and/or cite all data is<br>product under FTFRA sec. 3(c<br>inte of similar products to so<br>Make the labeling changes li<br>ment:<br>Add the obrase "FFA Peristran<br>The acute orai JD <sub>KO</sub> study su<br>spigmed is 255004.<br>The revised Confidential Star<br>acceptable and has been pla<br>Submit five (5) copies of yo<br>the product for shirment. R<br>ion of final printed labelin<br>here conditions are not come<br>to cancellation in accordanc<br>of the preduct constitutes<br>amued copy of the label is e | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>mistered in accordance<br>required for registre<br>((5) when the Agency<br>ubmit such data.<br>sted below before yo<br>tion No. 49840-2."<br>bmitted is accentable<br>tement of Forumla da<br>ced in your file.<br>ur final printed lab<br>efer to the A-79 Enc<br>d.<br>ifed with, the redist<br>e with FTEPA sec. ((<br>acceptance of these<br>inclosed for your rec<br>action R. Ice<br>Product Manager (31)                             | or cancel the registration of a product under t<br>ergistration of a product under t<br>or to its use if it has been cov<br>ce with FIFRA sec.<br>ation/reregistration<br>requires all<br>u release the produc<br>e. The accession<br>ted November 7,<br>whing before you<br>consure for a further<br>stration with he<br>e). Your pricase for<br>conditions. |
| health and the<br>icide in accord<br>Act is not to be<br>by others.<br>This<br>3(c)(7)(7)<br>i.<br>of your<br>repistran<br>2.<br>for ship<br>a.<br>3.<br>for ship<br>a.<br>3.<br>for ship<br>a.<br>3.<br>for ship<br>a.<br>3.<br>for ship<br>a.<br>3.<br>for ship<br>a.<br>5.<br>for ship<br>a.<br>for ship<br>a.<br>f | environment, the Administrator, on his mot<br>ance with the Act. The acceptance of any<br>e construed as giving the registrant a right<br>product is conditionally red<br>A) provided that you:<br>Submit and/or cite all data is<br>product under FTFRA sec. 3(c<br>ints of similar products to 5)<br>Make the labeling changes li<br>ment:<br>Add the phrase "FFA Fecistran<br>The acute oral ID50 study su<br>snicmed is 255004.<br>The revised Confidential Star<br>acceptable and has been pla<br>Submit five (5) copies of yo<br>the product for shimment. R<br>ion of final printed labelin<br>have conditions are not comp<br>to cancellation in accordanc<br>of the preduct constitutes<br>amimed copy of the label is e            | ion, may at any time suspend on<br>name in connection with the re-<br>to exclusive use of the name<br>mistered in accordance<br>required for registre<br>((5) when the Agency<br>ubmit such data.<br>sted below before yo<br>tion No. 49840-2."<br>bmitted is accentable<br>tement of Forumla da<br>ded in your file.<br>ur final printed lab<br>efer to the A-79 Enc<br>d.<br>ifed with, the redist<br>e with FTEPA sec. ((<br>acceptance of these<br>inclosed for your rec<br>d.<br>aoth R. Ice<br>Product Manager (31)<br>Disinfectants Branch | or cancel the registration of a product under t<br>ergistration of a product under t<br>or to its use if it has been cov<br>ce with FIFRA sec.<br>ation/reregistration<br>requires all<br>u release the produc<br>e. The accession<br>ted November 7,<br>whing before you<br>consure for a further<br>stration with he<br>e). Your pricase for<br>conditions. |

OF A MANAGER COPY

## PRESERVO TABLETS

## A PRESERVATIVE FOR LABORATORY SAMPLES OF

## MILK AND DAIRY PRODUCTS

# For Use in Analytical Testing Laboratories

| Active Ingredient:              |       |
|---------------------------------|-------|
| 2-bromo-2-nitropropane-1,3-diol | 9.22% |
|                                 |       |

Inert Ingredients:

<u>90.787</u> 100.007

KEEP OUT OF REACH OF CHILDREN

# DANGER

### PRECAUTIONARY STATEMENTS

Hazards to Humans and Domestic Animals

Corrosive. Causes eye damage and skin irritation. Do not get in eyes, bh'skin or on clothing. Harmful if swallowed. Wash 'thoroughly with soap and water after handling.Remove contaminated ''Clothing and wash before reuse.

Statement of Practical Treatment

... If inhåled - Remove victim to fresh air.

If swallowed- Promptly drink a large quantity of milk, egg whites, ""gelatin solution; or, if these are not available, drink large quantities of water. Avoid alcohol. Call a physician immediately. If in eyes- Flush with plenty of water. Get medical attention.

NOTE TO PHYSICIAN: Probable mucosal damage may contraindicate the use of gastric lavage. Measures against circulatory shock, respiratory depression, and convulsion may be needed.

EPA Est. No.49840—Ca.-1EPA Reg. No.49840—Net Weight: 2,600 gramsPatents PendingContents: 20,000 tablets

Dairy and Food Labs, Inc. 1750 Folsom Street San Francisco, Ca. 94103

ACCEPTED with COMMENTS in EPA Letter Dated;

DEC 07 1984

Under the Federal Insecticide, Fungicide, and Rodenticide Act as amended, for the pesticide registered under EPA Rcg. No. 49P40-2

### DIRECTIONS FOR USE

It is a violation of Federal law to use this product in a manner inconsistent with its labeling.

Use one (1) tablet per 2 oz. milk sample. Invert sample to mix. Do not overagitate. Tablet should be completely dissolved before testing. Preservo Tablets should be used within one year from date of manufacturing and within three months after opening.

## STORAGE AND DISPOSAL

Do not contaminate water, food or feed by storage or disposal.

(

**8** 8 2 8 8 8 п. н. <sub>1</sub>.

STORAGE: Tablets should be stored in a dry area at temperatures under 80°F. Dessicate after opening. Keep away from: oxidizing materials, metals, sources of ignition, food and food containers, sunlight and fluorescent lights.

PESTICIDE DISPOSAL:Wastes resulting from the use of this product may be disposed of on site or at an approved waste disposal facility.

CONTAINER DISPOSAL: Completely empty liner by shaking and tapping sides and bottom to loosen clinging particles. Empty residue into application 'equipment. Then dispose of liner and metal container in a sanitary landfill, or by incineration if allowed by state and local authorities. Dessicants may be removed and reused according to manufacturer's instructions.

> ACCEPTED with OOMMENTS in EPA Letter Dated:

- 1

PEGT Linitiane COP

DEC 07 1984

Under the Federal Insecticide. Fungicide, and Rodenticide Act an amended, for the pesticide registered under EPA Reg. No. 49840-3